4.8 Article

Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology

期刊

CIRCULATION
卷 135, 期 13, 页码 E793-+

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIR.0000000000000467

关键词

AHA Scientific Statements; cardiovascular diseases; morbidity; mortality; myocardial infarction; population; prevention; stroke

资金

  1. Center for Medicare and Medicaid Innovation
  2. National Cancer Institute
  3. NHLBI
  4. National Institute of Biomedical Imaging and Bioengineering
  5. Center for Medicare and Medicaid Innovation/The MITRE Corporation
  6. JR Alberts Foundation (FoodSwitch USA)
  7. World Heart Federation

向作者/读者索取更多资源

The Million Hearts Initiative has a goal of preventing 1 million heart attacks and strokes-the leading causes of mortality-through several public health and healthcare strategies by 2017. The American Heart Association and American College of Cardiology support the program. The Cardiovascular Risk Reduction Model was developed by Million Hearts and the Center for Medicare & Medicaid Services as a strategy to assess a value-based payment approach toward reduction in 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) by implementing cardiovascular preventive strategies to manage the ABCS (aspirin therapy in appropriate patients, blood pressure control, cholesterol management, and smoking cessation). The purpose of this special report is to describe the development and intended use of the Million Hearts Longitudinal ASCVD Risk Assessment Tool. The Million Hearts Tool reinforces and builds on the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk by allowing clinicians to estimate baseline and updated 10-year ASCVD risk estimates for primary prevention patients adhering to the appropriate ABCS over time, alone or in combination. The tool provides updated risk estimates based on evidence from high-quality systematic reviews and meta-analyses of the ABCS therapies. This novel approach to personalized estimation of benefits from risk-reducing therapies in primary prevention may help target therapies to those in whom they will provide the greatest benefit, and serves as the basis for a Center for Medicare & Medicaid Services program designed to evaluate the Million Hearts Cardiovascular Risk Reduction Model.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据